After signing up, you'll start to receive regular news updates from us.
Epizyme Achieves $4 Million Pre-Clinical Milestone Payment in Eisai Strategic Partnership
Complete the form below to unlock access to ALL audio articles.
Under the terms of the agreement, Epizyme may earn more than $200M in research, development and sales milestones and up to double-digit royalties. Additionally, Eisai will fund 100 percent of R&D through human proof-of-concept, at which point Epizyme has the right to opt into a profit share and co-commercialization arrangement for the United States.
Robert Copeland, Ph.D., EVP and CSO of Epizyme, said: "EZH2 is a very promising oncogenic target with strong validation in genetically-defined cancers, including subtypes of lymphoma and solid tumors with high unmet therapeutic needs. It has been less than a year since we began our partnership with Eisai. The significant progress we have made in this time affirms Epizyme's ability to discover and pursue small molecule histone methyltransferase inhibitors as personalized therapeutics for genetically-defined cancer patients."
The HMT class of epigenetic enzymes contains 96 members, many of which have strong genetic associations with cancer and other serious diseases. Targeting HMTs with potent and selective small molecule inhibitors offers an innovative therapeutic approach to controlling pathways of disease-causing gene expression.
